ImmunoGen, Inc. Announces Presentation Of HuN901-DM1 Clinical Data At EORTC-NCI-AACR Conference Showing Compound Is Well Tolerated And Demonstrates Anticancer Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced the presentation of clinical data from a Phase I study evaluating the Company’s huN901-DM1 anticancer agent for the treatment of small-cell lung cancer (SCLC) and other CD56-expressing solid tumors. The compound has been found to be well tolerated. Additionally, huN901-DM1 showed evidence of anticancer activity, including one complete remission in a patient with recurrent Merkel cell cancer and marked tumor shrinkage in a patient with relapsed SCLC.